Search research articles
Contact Us
Filters
Showing results (171-180 of 182) with videos related to
Page
of 19
Sort By:
HIV Medicine
|
September 23, 2021
Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study)
Ming Jie Lee, Luke Blagdon Snell, Sam T Douthwaite, et al.
Lancet (London, England)
|
September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
Sheena McCormack, David T Dunn, Monica Desai, et al.
AIDS (London, England)
|
May 31, 2024
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV
Leanne McCabe, James E Burns, Arash Latifoltojar, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial
Marcilio J Fumagalli, Anna Kaczynska, Marius Allombert, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy
Mohammed Altaf, Carla Nel, Timothy Tipoe, et al.
Nature Medicine
|
October 17, 2022
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
Jesper D Gunst, Marie H Pahus, Miriam Rosás-Umbert, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 6, 2026
A comparison of F/TAF and F/TDF as HIV pre-exposure prophylaxis in a predominantly cisgender women population in East and South Africa: a randomised, factorial, non-inferiority trial
Sheena McCormack, David Dunn, Sylvia Kusemererwa, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial
Ming Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV
|
May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial
Ming J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Sarah Fidler, Julie Fox, Timothy Tipoe, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 182) with videos related to
Sort By:
Page
of 19
HIV Medicine
|
September 23, 2021
Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study)
Ming Jie Lee, Luke Blagdon Snell, Sam T Douthwaite, et al.
Lancet (London, England)
|
September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
Sheena McCormack, David T Dunn, Monica Desai, et al.
AIDS (London, England)
|
May 31, 2024
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV
Leanne McCabe, James E Burns, Arash Latifoltojar, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial
Marcilio J Fumagalli, Anna Kaczynska, Marius Allombert, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy
Mohammed Altaf, Carla Nel, Timothy Tipoe, et al.
Nature Medicine
|
October 17, 2022
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
Jesper D Gunst, Marie H Pahus, Miriam Rosás-Umbert, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 6, 2026
A comparison of F/TAF and F/TDF as HIV pre-exposure prophylaxis in a predominantly cisgender women population in East and South Africa: a randomised, factorial, non-inferiority trial
Sheena McCormack, David Dunn, Sylvia Kusemererwa, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial
Ming Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV
|
May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial
Ming J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Sarah Fidler, Julie Fox, Timothy Tipoe, et al.
Page
of 19